Why was the Incannex share price put on ice today?

A capital raising is looming.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Incannex requested a trading halt today 
  • The medicinal cannabis products company intends to conduct a capital raising for institutional investors 
  • Incannex will resume trading as soon as a statement is made, or at the commencement of trading on Monday -- whichever comes first 

The Incannex Healthcare Ltd (ASX: IHL) share price went nowhere on Thursday after the company requested a trading halt before the market open.

The Incannex share price was 23 cents at the close yesterday.

Let's find out what's happening with this ASX cannabis share.

Man with his hand out the front, symbolising a trading halt.

Image source: Getty Images

Why is the Incannex share price at a standstill?

According to a statement, Incannex intends to conduct a "strategic institutional capital raising".

Incannex asked the ASX to halt its share trading ahead of an official announcement explaining the detail of the raising.

Incannex shares will remain on ice until the commencement of normal trading on 5 December or upon the release of its announcement.

What's been happening at Incannex?

Incannex develops medicinal cannabinoid pharmaceutical products.

As my Fool colleague Brooke recently noted, Incannex shares had a shocker in October.

The company entered the S&P/ASX 300 Index (ASX: XKO) in September. The following month, the Incannex share price underperformed the index by 15%. And that was despite a series of seemingly positive market updates.

In November, Incannex shares dropped another 11.5%. Ouch.

Cannabis shares are a highly volatile category of the market. One of their biggest hurdles is regulatory restrictions.

Medicinal cannabis is simply not legal in many parts of the world — including numerous states in the enormous nascent United States market.

As my Fool colleague Bernd reports, US President Joe Biden wants marijuana use legalised.

In October, he announced he would pardon everyone convicted of simple possession.

ASX cannabis shares responded to that, with Incannex shares rising 11% over two days.

Incannex performance snapshot

Incannex shares are down 65% in the year to date.

Over the past five years, they are up 1,050%.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why ResMed shares are tumbling 6% today despite strong results

Here's what spooked investors.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Imricor Medical Systems shares: Philips declares compatibility for iMR products

Big news is catching the eye of investors on Friday.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Earnings Results

ResMed posts strong Q4 earnings, lifts dividend

The sleep disorder treatment company had another record quarter.

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals reports clinical trial milestones

Clarity Pharmaceuticals reported continued clinical progress for its prostate cancer imaging and therapy programs.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?

This healthcare stock keeps rising.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose

Clarity Pharmaceuticals reports further progress in its SECuRE prostate cancer trial, showing strong PSA responses and new complete responses at…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade

Second quarter net sales of DAYBUE increased 30%.

Read more »